Publications by authors named "P Gijon"
Introduction: The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated and any long-term complications were characterized.
Methods: Between January 18 and March 16, 2022, 34 of the 45 adult patients who received therapy with plitidepsin in the APLICOV-PC study were enrolled in E-APLICOV (median time from plitidepsin first dose to E-APLICOV enrollment, 16.
The present outbreak of Human Monkeypox (HMPX) that has begun in May 2022 and has spread across all continents in less than two months has qualitative and quantitative characteristics that make it different from the pattern of human disease previously caused by this virus. It has spread with enormous ease, affects almost exclusively adults, behaves as a sexually transmitted disease and focuses on very specific groups and transmission conditions. The high incidence in the city of Madrid in males that have sex with males (MSM) has allowed us to observe and report the experience with the first 30 cases diagnosed in our institution.
View Article and Find Full Text PDFBackground And Purpose: Screening for and treatment of latent tuberculosis (TB) in patients with end-stage kidney disease (ESKD) are recommended. However, there is limited evidence on safety and treatment completion in this population. The objective of the study is to evaluate three short-course rifamycin-based regimens for the treatment of latent TB in ESKD patients.
View Article and Find Full Text PDFArticle Synopsis
- - Plitidepsin, a cyclic-peptide from marine sources, effectively inhibits SARS-CoV-2 replication by targeting an important host protein, showing its strongest effects in lung tissue compared to blood.
- - A clinical study involving 46 hospitalized COVID-19 patients tested three doses of plitidepsin and primarily focused on safety, while also monitoring viral load changes, mortality, and need for respiratory support.
- - The treatment was generally safe, with some common side effects like nausea, vomiting, and diarrhea; early results indicated significant reductions in viral load over time, though a few patients required additional medical support.
Unlabelled: Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A). We evaluated a model of intervention with plitidepsin in hospitalized COVID-19 adult patients where three doses were assessed (1.5, 2 and 2.
View Article and Find Full Text PDF